FIELD: medicine.
SUBSTANCE: invention relates to oncogynaecology, haematology and genetics, and aims at predicting the risk of malignant growths in cervix and endometrium, ovaries, breasts. For method implementation in females of reproductive age determine signs of hereditary disorders (HDCT) in connective tissue in different systems and organs, at least one genetic and at least one anamnestic factor of thrombogenic risk (FTR) and genital tract contamination. In compliance with detected signs low, medium or high risk of malignant growths in female genital organs and mammary glands is defined.
EFFECT: using the invention provides higher prediction accuracy and degree of malignant growths risk in cervix and endometrium, ovaries and breast.
1 cl, 3 dwg, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF BENIGN AND MALIGNANT NEOPLASMS OF OVARIES | 2018 |
|
RU2686180C1 |
| METHOD FOR PERICONCEPTIONAL PREDICTION OF RECURRENT EARLY REPRODUCTIVE LOSSES AND PRIMARY PLACENTAL INSUFFICIENCY | 2019 |
|
RU2709246C1 |
| METHOD FOR PREDICTION OF RISK OF UTERINE FIBROID | 2017 |
|
RU2650990C1 |
| METHOD FOR SELECTING UTERINE FIBROID MEDICINE THERAPY AND COMBINATION THEREOF WITH ADENOMYOSIS IN FEMALES | 2019 |
|
RU2718267C1 |
| METHOD FOR PREDICTION OF RISK OF DEVELOPMENT OF FEMALE GENITAL NEOPLASMS | 2018 |
|
RU2687780C1 |
| METHOD FOR PREDICTING THE RISK OF REPRODUCTIVE DISORDERS IN WOMEN WITH SUBCLINICAL AND OVERT HYPOTHYROIDISM | 2022 |
|
RU2804212C1 |
| METHOD AND REMEDY FOR TREATING BENIGN HYPERPLASIA PROCESSES IN ENDOMETRIUM | 2004 |
|
RU2275194C1 |
| METHOD OF DIFFERENTIATED USE OF DNA SEQUENCING DATA FOR PATIENTS AFTER KIDNEY TRANSPLANTATION | 2022 |
|
RU2803796C1 |
| METHOD FOR PRETERM DELIVERY PREDICTION | 2016 |
|
RU2626510C1 |
| METHOD FOR PREDICTION OF RISK OF RECURRENCE OF SYMPTOMATIC UTERINE MYOMA AFTER SELECTIVE EMBOLIZATION OF UTERINE ARTERIES | 2021 |
|
RU2766809C1 |
